Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: The Gynecologic Oncology Group experience

International Journal of Gynecological Cancer

Volumn 19, Issue 2, 2009, Pages 223-229

  Markman, Maurie ^a   Brady, Mark ^b   Hutson, Alan ^b   Berek, Jonathan S ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CISPLATIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; THIOTEPA; ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME; ADENOCARCINOMA; INFUSION; MIDDLE AGED; MORTALITY; OVARY TUMOR; SURVIVAL;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; INTERFERON ALFA-2B; INTERFERON-ALPHA; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THIOTEPA;

EID: 65649141236     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819bdc7e     Document Type: Article

References (22)

1. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4:277-283.
2. Markman M. Intraperitoneal chemotherapy. Crit Rev Oncol/Hem. 1999;31:239-246.
3. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955.
4. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
5. Armstrong DK, Bundy BN, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
6. Walker JL, Armstrong DK, Huang HO, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27-32.
7. Markman M, Blessing JA, Major F, et al. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study. Gynecol Oncol. 1993;50:191-195.
8. Feun LG, Blessing JA, Major FJ, et al. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1998;71:410-415.
9. Braly PS, Berek JS, Blessing JA, et al. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group trial. Gynecol Oncol. 1995;56:164-168.
10. Markman M, Berek JB, Blessing, et al. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant alpha-interferon. Gynecol Oncol. 1992;45:3-8.
11. Berek JS, Markman M, Blessing JA, et al. Intraperitoneal α-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol. 1999;74:48-52.
12. Berek JS, Markman M, Stonebraker B, et al. Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol. 1999;75:10-14.
13. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:2620-2624.
14. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5:1607-1612.
15. Recio FO, Piver MS, Hempling RE, et al. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol. 1998;68:267-273.
16. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol. 1992;10:1479-1484.
17. Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol. 2002;20:694-698.
18. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9: 1801-1805.
19. DeGregorio MW, Lum BL, Holleran WM, et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol. 1986;18:235-238.
20. Elferink F, van der Vijgh WJF, Klein I, et al. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol. 1988;21:57-60.
21. Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol. 1990;36:306-311.
22. Speyer JL, Beller U, Colombo N, et al. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol. 1990;8:1335-1341.